Drug intelligence / Profile preview

D-2-18F-α-methyl-phenylalanine

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

D-2-18F-α-methyl-phenylalanine is an F-18-labeled amino acid radiotracer developed for Positron Emission Tomography (PET) imaging. It is being evaluated for the diagnosis of various cancers, including bladder cancer, glioblastoma, and gliosarcoma. The drug is designed to leverage the increased amino acid metabolism and upregulated amino acid transporters in tumor cells, allowing for their visualization. Its properties include rapid blood clearance and low renal accumulation, which are advantageous for imaging applications where background radioactivity from urine can interfere, such as in bladder cancer detection.

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on D-2-18F-α-methyl-phenylalanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-2-18F-α-methyl-phenylalanine.

Explore the full profile